FindTrial
Sign In

Getting Biased Treatment Study: How Psychotherapy and Antidepressants Change Brain Activity in Chronic Depression

Impact of Therapeutical Strategies on Emotional Processing in Depression: Neurofunctional and Clinical Issues in the Context of Affective Bias

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00596986
Acronym
GETTY
Enrollment
30
Registered
2008-01-17
Start date
2008-10-31
Completion date
Unknown
Last updated
2009-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Depression

Keywords

Depression, Duloxetine, Psychotherapy, Magnetic Resonance Imaging

Brief summary

The purpose of this study is to determine how psychotherapy and pharmacotherapy respectively change brain activity in patients suffering from chronic depression.

Interventions

DRUGDuloxetine

Duloxetine 30mg up to 120mg per day.

BEHAVIORALCognitive Behavioural Analysis System of Psychotherapy

Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.

Sponsors

German Federal Ministry of Education and Research
CollaboratorOTHER_GOV
Charite University, Berlin, Germany
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
No

Inclusion criteria

* Chronic Depression (Double Depression, Chronic MDE, MDE with incomplete remission) * HAMD-24\>20

Exclusion criteria

* Concurrent Psychotherapy or Psychopharmacotherapy * Previous Non-Response to Duloxetine * Non-Response to three Antidepressants of two different groups given at adequate doses or Non-Response to two empirically tested forms of Psychotherapy in the current Depressive Episode * Serious Psychiatric comorbidity * Serious Neurologic comorbidity * Contraindications to Duloxetine * Contraindications to fMRI

Design outcomes

Primary

MeasureTime frame
Neuroimaging Data (fMRI)Before and After Therapy

Secondary

MeasureTime frame
HAMDWeekly
Salivary CortisolBefore and After Therapy

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026